Moreover, preclinical data showed that disruption of oncogenic signaling axes, the AMPKα (Thr172)/p-Drp1 (Ser637) or cyclin B1/Cdk1/p-Drp1 (Ser616) pathways by metformin or cucurbitacin E, respectively, significantly increased the sensitivity of NPC cells to cisplatin. The gene discussed is CDK1; the disease is nasopharyngeal carcinoma.